Furosemide (Lasix) Dosage Calculator for Dogs

Furosemide (Lasix) for Dogs – CHF Cornerstone Diuretic

Furosemide is the foundational loop diuretic for congestive heart failure (CHF) in dogs. This calculator uses the ACVIM MVD staging system to determine appropriate dosing.

ACVIM MVD Staging – When Furosemide Indicated

Standard Dose Table

Stage C ACUTE (IV in hospital)

Stage C STABLE (PO chronic maintenance)

Tablet sizes: 12.5, 20, 40, 50 mg (splittable). Injectable 50 mg/mL.

⚠ Stage B2 – DO NOT Start Furosemide

Per the EPIC trial (Boswood et al. 2016):

• Pimobendan in preclinical MVD with cardiomegaly delays CHF onset by ~15 months
• Furosemide in preclinical does NOT delay CHF
• Causes electrolyte derangements
• Activates RAAS counterproductively
• Reserve furosemide for Stage C onwards
• Stage B2 medication: Pimobendan 0.25 mg/kg PO q12h

CHF Triple/Quadruple Therapy

Critical Home Monitoring

Sleeping Respiratory Rate (SRR) – The #1 Parameter

• Count chest rises per minute while dog sleeping (not panting)
• Goal under 30 breaths per minute
• Sustained SRR over 30 = pulmonary edema returning → vet contact + dose increase
• More sensitive than cough monitoring
• Track daily in notebook or app
• Owners catch decompensation before crisis

Other Monitoring

• Body weight weekly – sudden gain = fluid retention; loss = dehydration
• Appetite – decreased = decompensation
• Energy level
• Cough frequency
• Water intake – markedly increased = excessive diuresis or CKD
• Urine output – should increase 1-2 hours post-dose

Bloodwork Schedule

• Baseline: BUN, creatinine, Na, K, Cl, USG before starting
• 1-2 weeks after starting or dose change
• Every 2-4 weeks initially
• Every 3-6 months once stable

Onset / Duration

Renal Dose Adjustments

Side Effects

• Polyuria/polydipsia (intended)
• Dehydration with excessive diuresis
• Prerenal azotemia (elevated BUN/Cr)
• Hypokalemia – very common (spironolactone helps prevent)
• Hyponatremia (dilutional)
• Hypochloremia + metabolic alkalosis
• Ototoxicity – rare, at high IV doses
• Hypotension

Questions This Calculator Answers

• “How much furosemide for my dog?” – Stage-based; 1-3 mg/kg stable, 4-8 mg/kg refractory
• “When increase dose?” – SRR sustained over 30, increased cough, weight gain
• “For preclinical B2?” – NO – pimobendan only
• “Furosemide + ACE-i?” – Standard combination; monitor BUN/Cr + K+
• “Side effects?” – Polyuria/polydipsia, dehydration, hypokalemia, azotemia
• “How fast does it work?” – PO 30-60 min, IV 5-10 min
• “Furosemide vs torsemide?” – Torsemide 10x more potent, longer-acting (refractory CHF)
• “For ascites?” – 2-4 mg/kg + spironolactone

Torsemide for Refractory CHF

• 10x more potent than furosemide
• Longer duration (12 vs 6 hours)
• Less affected by CKD
• Replacement OR adjunct: 0.1-0.6 mg/kg q12h
• 1 mg torsemide ≈ 10 mg furosemide
• Used for Stage D refractory cases

Drug Interactions

Contraindications

• Severe dehydration – stabilize first
• Severe hypokalemia (K under 2.5) – correct first
• Anuric AKI – vet decision
• Hypersensitivity (rare)

Never Abruptly Discontinue

In chronic CHF dog – NEVER suddenly stop furosemide. Acute discontinuation can trigger pulmonary edema crisis. Either:

• Taper slowly if discontinuing
• Replace with torsemide
• Continue chronic dosing

Conclusion

Furosemide is the cornerstone CHF diuretic at 1-3 mg/kg PO q8-12h stable to 4-8 mg/kg refractory. Stage B2 preclinical = pimobendan only. Stage C requires triple/quad therapy (furo + pimo + ACE-i + spironolactone). Sleeping respiratory rate (goal <30/min) is the single most important home monitoring parameter. Bloodwork every 2-4 weeks initially. Torsemide for refractory cases. Never abruptly discontinue.

Frequently Asked Questions

How much furosemide can I give my dog with heart failure?

DEPENDS ON ACVIM STAGE – dose varies dramatically. STAGE C ACUTE (pulmonary edema crisis in hospital): 2-4 mg/kg IV every 1-2 hours until respiratory rate under 40/min, then transition to oral. STAGE C STABLE (post-CHF maintenance at home): 1-3 mg/kg PO every 8-12 hours. STAGE C JUST-DISCHARGED (first 1-2 weeks post-CHF): 2-4 mg/kg PO every 8 hours, then taper to maintenance. STAGE D REFRACTORY (recurrent CHF on triple therapy): 4-8 mg/kg PO every 8 hours; consider TORSEMIDE 0.1-0.6 mg/kg q12h as more potent replacement or adjunct. STAGE B2 PRECLINICAL: NO furosemide – PIMOBENDAN 0.25 mg/kg PO q12h per EPIC trial. EXAMPLES (Stage C stable PO): 1) 5 kg dog: 5-15 mg PO q12h; 2) 10 kg: 10-30 mg q12h; 3) 15 kg: 15-45 mg q12h; 4) 20 kg: 20-60 mg q12h; 5) 30 kg: 30-90 mg q12h; 6) 40 kg: 40-120 mg q12h. TABLETS: 12.5, 20, 40, 50 mg – splittable; INJECTABLE: 50 mg/mL; LIQUID compounded 10 mg/mL available. RENAL ADJUSTMENTS: 1) Normal kidney function – standard dose; 2) IRIS 2 CKD – 1.2x dose; 3) IRIS 3 – 1.5x dose; 4) IRIS 4 – up to 2x or switch torsemide; 5) AKI – vet decision needed. STANDARD CHF MANAGEMENT: 1) Furosemide alone insufficient; 2) PIMOBENDAN 0.25 mg/kg PO q12h essential; 3) ACE-INHIBITOR (benazepril 0.5 mg/kg q24h or enalapril 0.5 mg/kg q12h); 4) SPIRONOLACTONE 2 mg/kg q24h – potassium-sparing diuretic adjunct; 5) Possible HYDROCHLOROTHIAZIDE 2-4 mg/kg q12h for refractory. DOSE ADJUSTMENT STRATEGY: 1) Track SLEEPING respiratory rate (SRR) – goal under 30/min; 2) If SRR over 30 sustained = pulmonary edema returning; 3) Increase dose 25-50% or add dose; 4) If SRR creeping up – dose increase; 5) Monitor weight, appetite, energy; 6) Bloodwork every 2-4 weeks initially, then 3-6 months stable. NEVER abruptly discontinue chronic furosemide – can trigger acute CHF crisis. Taper or replace if needed. WORK WITH VETERINARIAN – chronic CHF management requires regular re-evaluation, dose adjustment based on response + side effects, electrolyte monitoring, renal function tracking. Cardiology consultation valuable for refractory cases.

What are signs of CHF returning in my dog on furosemide?

SLEEPING RESPIRATORY RATE (SRR) > 30 is the EARLIEST sign – monitor daily. CRITICAL HOME MONITORING: 1) SLEEPING RESPIRATORY RATE: a) Count breaths per minute while dog SLEEPING (not panting, not anxious); b) Goal under 30 breaths per minute; c) SUSTAINED OVER 30 = pulmonary edema returning; d) Track daily in log/app; e) MOST SENSITIVE indicator – catches CHF before crisis; f) Free home test; g) Can save dog’s life; 2) RESPIRATORY EFFORT: a) Increased work of breathing; b) Abdominal effort; c) Open-mouth breathing while resting; d) Restless when trying to rest; e) Cannot get comfortable; f) Standing/sitting rather than lying down; 3) COUGH: a) Increased frequency; b) Nighttime cough; c) Cough triggered by lying down; d) Productive cough (foamy/pink); e) Cough that wakes dog from sleep; 4) ENERGY: a) Decreased exercise tolerance; b) Tires faster on walks; c) Reluctant to play; d) Lethargy; e) Decreased interest in normal activities; 5) APPETITE: a) Decreased food intake; b) Refusing favorite treats; c) Weight loss (cardiac cachexia); 6) DEMEANOR: a) Hiding; b) Restless; c) Anxious; d) Pacing; 7) BODY WEIGHT: a) Sudden gain over 5% in 1-2 days = fluid retention; b) Track weekly; c) Sudden loss = dehydration or anorexia; 8) URINATION: a) Decreased urine output = poor cardiac output or dehydration; b) Increased very pale urine = excessive diuresis; 9) ABDOMEN: a) Distention from ascites (right-sided CHF); b) Doughy feel; c) Heavy (‘water balloon’); 10) MUCOUS MEMBRANES: a) Pale – poor perfusion; b) Cyanotic (blue/purple) – oxygenation problem – EMERGENCY; c) Capillary refill prolonged. EMERGENCY signs requiring IMMEDIATE vet: 1) Severe respiratory distress; 2) Open-mouth breathing not exercise-related; 3) Cyanosis (blue gums/tongue); 4) Collapse; 5) Coughing up pink foamy fluid; 6) Inability to lie down (orthopnea); 7) Severe restlessness, panic; 8) Syncope (fainting). WHEN TO CONTACT VET: 1) SRR consistently over 30 for more than 2 days; 2) New or worsening cough; 3) Decreased appetite over 24 hours; 4) Decreased energy notably; 5) Weight gain 3-5%; 6) Side effects from medications; 7) Any new concerning sign. ACTION STEPS IF SRR OVER 30: 1) Confirm with multiple counts over 24 hours; 2) Document SRR readings; 3) Note other symptoms; 4) Contact vet for guidance; 5) May need dose increase; 6) May need vet visit + chest X-rays; 7) May need IV diuretic in hospital. PROACTIVE STRATEGIES to prevent decompensation: 1) Strict medication compliance; 2) Avoid high-sodium foods/treats; 3) Maintain quality diet (consider cardiac diet); 4) Regular vet rechecks; 5) Periodic bloodwork; 6) Routine echocardiogram if cardiology managed; 7) Owner education on monitoring; 8) Emergency plan if decompensation; 9) Avoid extreme exertion; 10) Climate management (cooling). CARDIAC DIETS: 1) Sodium-restricted (less than 0.1% sodium dry matter); 2) Hill’s h/d, Royal Canin Early Cardiac, Purina CardioCare; 3) Adequate protein + calories; 4) Omega-3 supplementation; 5) Coenzyme Q10 sometimes added; 6) Taurine if breed predisposition. EXERCISE GUIDANCE: 1) Stable Stage C – moderate exercise to tolerance; 2) Acute decompensation – rest; 3) Refractory – very limited; 4) Avoid extreme weather, exertion, stress; 5) Short frequent walks vs long; 6) Allow rest breaks. END-OF-LIFE indicators: 1) Refractory to maximum therapy; 2) Recurrent crises; 3) Poor quality of life days outweigh good; 4) Cannot eat/drink; 5) Persistent dyspnea; 6) Cardiac cachexia advanced; 7) Multiple organ dysfunction; 8) Time for hospice/palliative discussion.

Is furosemide safe for dogs?

YES – WHEN PROPERLY MANAGED with regular monitoring. NOT WITHOUT RISK – requires veterinary oversight. SAFE PROFILE: 1) Standard CHF treatment for decades; 2) Well-studied in dogs; 3) Generally well-tolerated at therapeutic doses; 4) Reversible side effects with proper monitoring; 5) Essential for CHF dogs – benefits exceed risks; 6) Inexpensive; 7) Widely available; 8) Generic standard. RISK PROFILE: 1) Dehydration – common with excessive doses or concurrent illness; 2) Hypokalemia – very common chronic use; 3) Prerenal azotemia (elevated BUN/Cr from dehydration); 4) Hyponatremia – dilutional; 5) Metabolic alkalosis – chronic high-dose; 6) Ototoxicity – rare, high IV doses (especially aminoglycoside combo); 7) Hypotension – excessive diuresis. CONTRAINDICATIONS: 1) Severe dehydration – stabilize first with IV fluids; 2) Severe hypokalemia (K under 2.5) – correct first; 3) Hypersensitivity to sulfonamides (cross-reactivity with furosemide); 4) Anuric AKI; 5) Hepatic encephalopathy – electrolyte derangements worsen; 6) Coma. CAUTIONS: 1) Diabetes – alters glucose control; 2) Hyperuricemia; 3) Liver disease; 4) SLE; 5) Hearing impairment; 6) Pregnancy – generally avoided but used if necessary; 7) Lactation – excreted in milk; 8) Geriatric dogs – more side effect prone. PRECLINICAL B2 – DO NOT USE: 1) EPIC trial shows pimobendan delays CHF; 2) Furosemide does not delay CHF in B2; 3) Causes side effects unnecessarily; 4) Activates RAAS counterproductively; 5) Reserve for Stage C clinical CHF. MONITORING REQUIRED: 1) BASELINE BUN, creatinine, Na, K, Cl, USG before starting; 2) RECHECK 1-2 weeks after starting or dose change; 3) EVERY 2-4 weeks initially; 4) EVERY 3-6 months once stable; 5) HOME MONITORING – SRR daily, weight weekly, appetite, energy, cough; 6) BLOOD PRESSURE periodically; 7) ECG if arrhythmia concern. DRUG INTERACTIONS: 1) ACE-INHIBITORS (benazepril, enalapril) – standard combination but additive renal/K+ effects; monitor; 2) SPIRONOLACTONE – K+-sparing adjunct; recommended; 3) NSAIDs – reduce diuretic effect + increase renal risk; AVOID if possible; 4) AMINOGLYCOSIDE antibiotics – additive ototoxicity; 5) DIGOXIN – K+ changes affect digoxin toxicity; 6) CORTICOSTEROIDS – additive K+ loss; 7) LITHIUM – increased levels (rare in vet); 8) MUSCLE RELAXANTS potentiated; 9) PROBENECID – decreased diuretic effect. SIDE EFFECTS by frequency: COMMON: 1) Polyuria (excessive urination – intended); 2) Polydipsia (increased thirst); 3) Hypokalemia; 4) Mild prerenal azotemia. UNCOMMON: 1) Dehydration; 2) Hyponatremia; 3) Hypotension; 4) Anorexia; 5) GI upset; 6) Hypochloremia + metabolic alkalosis. RARE: 1) Ototoxicity; 2) Severe dehydration; 3) Anaphylaxis; 4) Blood dyscrasias; 5) Acute pancreatitis. OVERDOSE: 1) Severe dehydration; 2) Profound electrolyte derangements; 3) Hypotension, shock; 4) Acute renal failure; 5) Treatment: IV fluids, electrolyte correction, supportive care. PRACTICAL SAFETY: 1) Use prescribed dose – don’t adjust without vet; 2) Monitor SRR, weight, appetite; 3) Maintain water access always; 4) Cardiac diet (sodium-restricted); 5) Regular vet recheck; 6) Periodic bloodwork; 7) Report side effects promptly; 8) Watch for drug interactions; 9) Don’t combine with NSAIDs; 10) Owner education essential. NEVER abruptly discontinue chronic furosemide – taper if discontinuing, replace with torsemide if changing, continue if stable. Acute discontinuation can trigger pulmonary edema crisis. CARDIOLOGY CONSULT valuable: 1) Complex CHF management; 2) Refractory cases; 3) Multiple comorbidities; 4) Multiple medications; 5) Stage D management; 6) Quality of life decisions.

Why does my CHF dog drink so much water and urinate so much on furosemide?

EXPECTED + INTENDED EFFECT of loop diuretic. Furosemide works by blocking sodium reabsorption in the loop of Henle = water follows sodium = increased urine output. SOMEWHAT NORMAL: 1) POLYURIA (increased urination) – intended therapeutic effect; 2) POLYDIPSIA (increased thirst) – compensatory response to fluid loss; 3) WATER AT BOWL EMPTY frequently; 4) Multiple urinations per day; 5) Larger urine volume per void; 6) Some dogs wake at night to urinate; 7) Pale dilute urine. PROBLEM IF EXCESSIVE: 1) DEHYDRATION can develop; 2) Electrolyte derangements; 3) Prerenal azotemia; 4) Decreased renal function; 5) Quality of life concerns (frequent outdoor trips); 6) Sleep disruption (owner + dog). WATER INTAKE EXPECTATIONS on furosemide: 1) NORMAL DOG: 60-100 mL/kg/day; 2) DOG ON FUROSEMIDE: 80-150 mL/kg/day typical; 3) Highly variable individually; 4) Track over time to know baseline; 5) MARKED INCREASE over baseline = concern. CAUSES of EXCESSIVE water intake/urination: 1) Furosemide dose appropriate but expected diuresis; 2) Furosemide DOSE TOO HIGH – reduce or assess; 3) DEHYDRATION compensating – vet visit; 4) CONCURRENT CKD progression – common in older dogs; 5) DIABETES MELLITUS – polyuria/polydipsia from hyperglycemia; 6) DIABETES INSIPIDUS rare; 7) CUSHING’S DISEASE comorbidity; 8) PYOMETRA in intact female; 9) LIVER DISEASE; 10) HYPERCALCEMIA (cancer paraneoplastic). MANAGEMENT: 1) ENSURE ADEQUATE WATER ACCESS always – multiple bowls, larger bowls, refill frequently; 2) APPROPRIATE outdoor access – frequent breaks, especially after meal + dose; 3) ABSORBENT PADS indoor if needed; 4) DOGGY DOOR if possible; 5) AVOID restricting water intake – causes dehydration; 6) MONITOR water intake to track changes; 7) Adjust DOSE TIMING – avoid late evening dose if possible (less nighttime urination). DOSE TIMING for owner convenience: 1) Last dose by 6-7 PM if possible; 2) Earliest dose at wake time (5-7 AM); 3) BID dosing – 7 AM + 7 PM standard; 4) TID dosing – 7 AM + 1 PM + 7 PM; 5) Some dogs can dose 8 AM + 2 PM + 8 PM; 6) Account for owner schedule; 7) Multi-dog household considerations; 8) Outdoor access availability. WHEN TO CONCERN: 1) Sudden increase in water/urination beyond baseline; 2) Decreased intake (uncommon – more concerning); 3) Concurrent decreased appetite; 4) Lethargy + increased intake; 5) Vomiting; 6) Sudden weight loss; 7) Difficulty getting to bathroom; 8) Accidents in trained dog; 9) Diluted very pale urine constantly; 10) Strong concentrated dark urine. SIGNS OF DEHYDRATION despite increased intake: 1) Tacky/dry gums; 2) Skin tent prolonged; 3) Sunken eyes; 4) Lethargy; 5) Decreased appetite; 6) Weight loss; 7) Elevated BUN/Cr on bloodwork. VET ASSESSMENT if concerns: 1) Bloodwork – BUN, Cr, Na, K, Cl, glucose; 2) URINALYSIS – USG, glucose, protein, sediment; 3) Urine culture if signs of infection; 4) Blood pressure; 5) Reassess CHF status; 6) Adjust furosemide dose if needed; 7) Consider torsemide if excessive doses; 8) Investigate concurrent conditions. CONCURRENT CONDITION SCREENING: 1) Annual senior wellness exam; 2) Diabetes screening (especially if PU/PD increasing); 3) Cushing’s screening (if other signs); 4) CKD staging (IRIS); 5) Liver function; 6) Calcium levels. TIPS for nighttime: 1) Last dose timing earlier; 2) Outdoor access close to bedtime; 3) Limit food/water 1-2 hours before bed (but ensure access during day); 4) Doggy door; 5) Belly band male dogs (incontinence); 6) Diaper female dogs; 7) Washable bedding/mattress protector. QUALITY OF LIFE: 1) Frequent urination is normal CHF management cost; 2) Better than the alternative (pulmonary edema); 3) Most dogs adapt well; 4) Owner adapts routine; 5) Discussion with vet if quality concerns. NEVER restrict water intake – causes dehydration + worsens kidney function + may trigger CHF crisis. Always ensure water available.

Can I give my dog NSAIDs (like carprofen) with furosemide?

AVOID if possible – significant drug interaction. WHY THE INTERACTION: 1) NSAIDs inhibit prostaglandin synthesis; 2) Prostaglandins maintain renal blood flow especially in volume-depleted state; 3) Furosemide causes volume depletion; 4) NSAIDs + furosemide-induced volume depletion = decreased renal blood flow; 5) Result: ACUTE KIDNEY INJURY risk significantly increased; 6) Furosemide effect also reduced by NSAIDs; 7) Additive GI ulcer risk if concurrent steroids. RISK FACTORS for severe interaction: 1) Older age; 2) Pre-existing CKD; 3) Dehydration; 4) High furosemide dose; 5) Concurrent ACE-inhibitor (triple-whammy effect); 6) Long-term concurrent use; 7) Hypovolemia. TRIPLE WHAMMY: 1) ACE-INHIBITOR + DIURETIC + NSAID = significantly increased AKI risk; 2) Common scenario in CHF dog with arthritis; 3) Each medication appropriate individually; 4) Combination problematic; 5) Documented in human + veterinary medicine. SAFER ALTERNATIVES for CHF dog with pain/arthritis: 1) GABAPENTIN 10-20 mg/kg q8-12h – no renal/GI issues; 2) OMEGA-3 (fish oil) anti-inflammatory; 3) ADEQUAN (PSGAG) injections; 4) GLUCOSAMINE/CHONDROITIN supplements (Dasuquin, Cosequin); 5) GREEN-LIPPED MUSSEL supplements; 6) ACUPUNCTURE; 7) LASER THERAPY (Class IV); 8) PHYSICAL THERAPY/HYDROTHERAPY; 9) WEIGHT MANAGEMENT (if overweight); 10) MAROPITANT (Cerenia) – mild anti-inflammatory; 11) AMANTADINE for chronic pain; 12) TRAMADOL (limited efficacy but safer than NSAID); 13) GRAPIPRANT (Galliprant) – EP4 antagonist, may be slightly safer than COX inhibitors but still NSAID class – use cautiously; 14) LIBRELA (bedinvetmab) – anti-NGF monoclonal antibody – NEWER OPTION – safer profile than NSAIDs – excellent for CHF dogs needing arthritis treatment; 15) CYTOPOINT for pruritus; 16) THERAPEUTIC DIETS (Hill’s j/d, Royal Canin Mobility) with built-in omega-3 + glucosamine. IF NSAID NECESSARY (after exhausting alternatives): 1) Vet decision with informed consent; 2) Cardiology + nephrology consultation if possible; 3) Use LOWEST effective dose; 4) Use SHORTEST possible duration; 5) MONITOR bloodwork weekly initially: BUN, Cr, Na, K, USG, ALT; 6) MONITOR blood pressure; 7) Ensure ADEQUATE hydration; 8) AVOID dehydration (don’t reduce water intake); 9) WATCH for AKI signs – vomiting, anorexia, lethargy, decreased urine; 10) ELECTROLYTE monitoring; 11) Consider PPI (omeprazole) for GI protection; 12) Stop at first sign of trouble; 13) Discuss prognosis – CHF dogs have limited reserve. AKI WARNING SIGNS in CHF dog on NSAID + furosemide: 1) DECREASED appetite; 2) VOMITING; 3) LETHARGY; 4) Decreased urine output; 5) Increased BUN/Cr on bloodwork; 6) Decreased urine specific gravity; 7) Increased lethargy; 8) Dehydration despite water intake; 9) Tremors, weakness; 10) Collapse. ACTION: STOP NSAID immediately + vet visit. SPECIFIC NSAIDS to avoid in CHF dog: 1) Carprofen (Rimadyl, Novox, Vetprofen); 2) Meloxicam (Metacam, Loxicom, Meloxidyl); 3) Firocoxib (Previcox); 4) Robenacoxib (Onsior); 5) Deracoxib (Deramaxx); 6) Aspirin (in addition – cardiac concerns); 7) Human NSAIDs (NEVER); 8) Galliprant (Grapiprant) – safer profile but still NSAID class – use very cautiously. RECOMMENDED: NON-NSAID multimodal pain management for CHF dogs: 1) Gabapentin baseline; 2) Adequan or polysulfated GAG injections; 3) Omega-3 supplementation; 4) Joint supplements; 5) Acupuncture; 6) Physical therapy; 7) Weight management; 8) Librela for monthly injection (anti-NGF); 9) Maropitant for daily ANALGESIA + anti-inflammatory; 10) Amantadine for chronic pain. WORK WITH VETERINARIAN to develop balanced plan addressing both cardiac and orthopedic needs while minimizing iatrogenic complications. Many CHF dogs can have good quality of life with non-NSAID arthritis management.

What is the difference between furosemide and torsemide for dogs?

BOTH are LOOP DIURETICS but TORSEMIDE is more potent, longer-acting, and less affected by CKD. KEY DIFFERENCES: 1) POTENCY: torsemide ~10x more potent than furosemide; 1 mg torsemide ~ 10 mg furosemide; 2) DURATION: torsemide 12+ hours vs furosemide 6-8 hours; 3) BIOAVAILABILITY: torsemide ~90% oral bioavailability vs furosemide ~50% (more consistent absorption); 4) HALF-LIFE: torsemide 6 hours vs furosemide 2 hours; 5) RENAL DEPENDENCE: torsemide less affected by CKD (more reliable diuresis); 6) CHRONIC USE: less tolerance development with torsemide; 7) HYPOKALEMIA: torsemide may cause less than furosemide (less data); 8) ALDOSTERONE ANTAGONISM: torsemide has mild anti-aldosterone effect (advantage); 9) COST: torsemide more expensive but lower dose needed. WHEN TO USE TORSEMIDE: 1) REFRACTORY CHF on maximum furosemide; 2) CKD with declining furosemide response; 3) Dogs requiring high-dose furosemide; 4) Less frequent dosing needed; 5) Better quality of life; 6) Stage D CHF; 7) Recurrent crises on furosemide. CONVERSION FUROSEMIDE TO TORSEMIDE: 1) Calculate total daily furosemide dose; 2) Divide by 10-20 (more conservative starting); 3) Give as twice-daily torsemide; 4) EXAMPLE: 4 mg/kg furosemide BID = 8 mg/kg/day = 0.4-0.8 mg/kg/day torsemide = 0.2-0.4 mg/kg BID; 5) START LOWER end; 6) Titrate based on response; 7) Monitor closely first 1-2 weeks. WHEN TO STAY WITH FUROSEMIDE: 1) Stable Stage C CHF responding well; 2) Cost concern; 3) Owner-administered injectable for acute episodes; 4) Acute CHF crisis (IV furosemide standard); 5) Early/mild CHF; 6) Most cases initially. STARTING DOSE TORSEMIDE: 1) 0.1-0.6 mg/kg PO every 12 hours typical; 2) START 0.1-0.2 mg/kg BID if naive; 3) Titrate up based on respiratory rate response; 4) Maximum 0.6-0.8 mg/kg q12h; 5) Higher doses uncommon. MONITORING SIMILAR TO FUROSEMIDE: 1) Sleeping respiratory rate (SRR); 2) Body weight; 3) Renal values; 4) Electrolytes (especially K+); 5) Hydration; 6) Appetite + energy; 7) Quality of life. SIDE EFFECTS – similar to furosemide: 1) Polyuria/polydipsia; 2) Dehydration; 3) Hypokalemia (possibly less than furosemide); 4) Prerenal azotemia; 5) Hyponatremia; 6) GI upset uncommon. CONTRAINDICATIONS – similar: 1) Severe dehydration; 2) Severe hypokalemia; 3) Hypersensitivity (sulfonamide-class); 4) Anuria. ADVANTAGES of TORSEMIDE: 1) More predictable response; 2) Less affected by CKD; 3) Less frequent dosing; 4) Better bioavailability; 5) Mild aldosterone antagonism; 6) Less tolerance over time; 7) May allow lower combined diuretic burden. DISADVANTAGES: 1) More expensive; 2) Less familiar to some vets; 3) Smaller body of veterinary literature; 4) Different tablet sizes; 5) May need compounding for small dogs; 6) Dose adjustments per individual. COMBINATION DIURETIC THERAPY: 1) FUROSEMIDE + TORSEMIDE – some refractory CHF; 2) FUROSEMIDE + HYDROCHLOROTHIAZIDE – sequential nephron blockade; 3) FUROSEMIDE + SPIRONOLACTONE – standard adjunct; 4) TORSEMIDE + SPIRONOLACTONE; 5) Triple diuretic – very refractory; 6) Monitor electrolytes closely with combinations. SWITCHING STRATEGY: 1) Discuss with vet/cardiologist; 2) Calculate equivalent dose; 3) Start lower than calculated; 4) Discontinue furosemide; 5) Monitor first 1-2 weeks intensively; 6) Adjust based on response; 7) Continue other CHF medications; 8) Re-check bloodwork at 1 week; 9) Re-evaluate at 2-4 weeks. END-STAGE CHF CONSIDERATIONS: 1) Maximum diuretic therapy; 2) Quality of life assessment; 3) Hospice care discussion; 4) Realistic expectations; 5) Comfort measures; 6) When to consider euthanasia; 7) Owner support. PROGNOSIS varies: 1) Stage C – typically 1-3 years from CHF diagnosis with optimal management; 2) Stage D – months; 3) Individual variation significant; 4) Response to therapy predicts; 5) Quality of life primary goal.

Related PuppaDogs Calculators

Continue building your dog’s personalised care plan with these related PuppaDogs calculators:

• Dog Pregnancy / Whelping Due-Date Calculator
• Puppy Weight Predictor (Adult Weight Calculator)
• Heatstroke Risk Calculator for Dogs
• Bloat (GDV) Risk Calculator for Dogs
• Dog Life Expectancy Calculator (Breed, Body Condition, Lifestyle)
• Spay/Neuter Timing Calculator for Dogs (Breed-Specific)

Related Articles & Guides

Read the in-depth PuppaDogs guides that explain the science and clinical context behind this calculator:

• Lasix for Dogs: Benefits, Dosage, Side Effects, and More

References & Further Reading

The dosing ranges and safety information on this page are drawn from the following veterinary references. Always defer to your own veterinarian and the manufacturer’s label for your specific product.

1. Boswood A et al. Effect of pimobendan in dogs with preclinical myxomatous mitral valve disease and cardiomegaly: The EPIC Study. JVIM 2016.
2. Keene BW et al. ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs. JVIM 2019.
3. Atkins C et al. Guidelines for the diagnosis and treatment of canine chronic valvular heart disease. JVIM 2009.
4. Plumb DC. Plumb’s Veterinary Drug Handbook – furosemide.
5. Ettinger SJ, Feldman EC. Textbook of Veterinary Internal Medicine.
6. Fox PR et al. Textbook of Canine and Feline Cardiology.
7. Smith FWK, Tilley LP. Manual of Canine and Feline Cardiology.
8. Chetboul V et al. Comparative pharmacokinetics of furosemide. JVIM.
9. Hezzell MJ et al. Torsemide vs furosemide in dogs with refractory CHF. JVIM.
10. Adin DB. Furosemide use in dogs. ACVIM Forum proceedings.
11. Oyama MA. Cardiac biomarkers for the diagnosis of congestive heart failure.
12. Borgarelli M, Buchanan JW. Historical review, epidemiology and natural history of degenerative mitral valve disease.
13. PuppaDogs. Mitral Valve Disease ACVIM Stage Calculator, Resting Respiratory Rate Calculator, Heart Murmur Grade Interpreter, IRIS Kidney Disease Staging Calculator. puppadogs.com.

Suyash Dhoot